JP2022529726A - Ａｎｔｉ－ｃｄ１１７とその使用 - Google Patents

Ａｎｔｉ－ｃｄ１１７とその使用 Download PDF

Info

Publication number
JP2022529726A
JP2022529726A JP2021562911A JP2021562911A JP2022529726A JP 2022529726 A JP2022529726 A JP 2022529726A JP 2021562911 A JP2021562911 A JP 2021562911A JP 2021562911 A JP2021562911 A JP 2021562911A JP 2022529726 A JP2022529726 A JP 2022529726A
Authority
JP
Japan
Prior art keywords
antigen
seq
amino acid
binding fragment
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021562911A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529726A5 (https=
JPWO2020219770A5 (https=
Inventor
パルチョウデュリー ラーフル
ボイタノ アンソニー
クック マイケル
アール ピアース ブラッドリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dianthus Therapeutics Inc
Original Assignee
Magenta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magenta Therapeutics Inc filed Critical Magenta Therapeutics Inc
Publication of JP2022529726A publication Critical patent/JP2022529726A/ja
Publication of JP2022529726A5 publication Critical patent/JP2022529726A5/ja
Publication of JPWO2020219770A5 publication Critical patent/JPWO2020219770A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021562911A 2019-04-24 2020-04-23 Ａｎｔｉ－ｃｄ１１７とその使用 Withdrawn JP2022529726A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962838264P 2019-04-24 2019-04-24
US62/838,264 2019-04-24
US201962841733P 2019-05-01 2019-05-01
US62/841,733 2019-05-01
PCT/US2020/029648 WO2020219770A1 (en) 2019-04-24 2020-04-23 Anti-cd117 antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2022529726A true JP2022529726A (ja) 2022-06-23
JP2022529726A5 JP2022529726A5 (https=) 2022-09-20
JPWO2020219770A5 JPWO2020219770A5 (https=) 2022-09-20

Family

ID=72941829

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021562911A Withdrawn JP2022529726A (ja) 2019-04-24 2020-04-23 Ａｎｔｉ－ｃｄ１１７とその使用

Country Status (7)

Country Link
US (1) US20220177575A1 (https=)
EP (1) EP3958902A4 (https=)
JP (1) JP2022529726A (https=)
CN (1) CN114007644A (https=)
AU (1) AU2020261405A1 (https=)
CA (1) CA3134319A1 (https=)
WO (1) WO2020219770A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121555430A (zh) 2018-05-11 2026-02-24 比姆医疗股份有限公司 使用可编程碱基编辑器系统取代病原性氨基酸的方法
EP3959242A4 (en) * 2019-04-24 2023-09-13 Magenta Therapeutics, Inc. ANTRACYCLINE ANTIBODY-DRUG CONJUGATES AND THEIR USES
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086044A1 (es) * 2011-05-12 2013-11-13 Imclone Llc Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
US10421802B2 (en) * 2013-10-18 2019-09-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies against the middle east respiratory syndrome coronavirus (MERS-CoV) and engineered bispecific fusions with inhibitory peptides
CA3079897A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd117+ cells

Also Published As

Publication number Publication date
EP3958902A1 (en) 2022-03-02
WO2020219770A1 (en) 2020-10-29
CN114007644A (zh) 2022-02-01
EP3958902A4 (en) 2023-01-25
CA3134319A1 (en) 2020-10-29
AU2020261405A1 (en) 2021-12-23
US20220177575A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
JP2022529726A (ja) Ａｎｔｉ－ｃｄ１１７とその使用
JP2022512778A (ja) 抗－ｃｄ４５抗体及びそのコンジュゲート
JP2022530089A (ja) 抗ｃｄ４５抗体薬物結合体とその利用法
TWI904109B (zh) 抗ｃｄ４５抗體及其結合物
KR20200069364A (ko) Cd117+ 세포의 고갈을 위한 조성물 및 방법
JP2021500391A (ja) Ｃｄ１１７＋細胞を減少させるための組成物及び方法
KR20210081393A (ko) Fc 침묵 항체 약물 컨쥬게이트(ADC) 및 이의 용도
JP2021500375A5 (https=)
JP2021504412A (ja) Ｃｄ５＋細胞の枯渇のための組成物および方法
CN114174317A (zh) 鹅膏毒素抗体-药物缀合物及其用途
JP2022529726A5 (https=)
JP2022530438A (ja) 抗ｃｄ１１７抗体薬物複合体およびその使用
JP2022530443A (ja) 抗ｃｄ１１７抗体薬物複合体およびその使用
JP2021504414A (ja) Ｃｄ２＋細胞の枯渇のための組成物および方法
JP2022531141A (ja) 遺伝子治療のコンディショニング方法
JP2022530443A5 (https=)
JP2022530442A (ja) アントラサイクリン抗体薬物複合体およびその使用
US20220177578A1 (en) Anti-cd117 antibodies and uses thereof
JP2022518150A (ja) 細胞療法での抗ｃｄ４５抗体－薬物結合体（ａｄｃ）の使用経験
JP2022529727A5 (https=)
KR20220154676A (ko) 동종 이식을 위한 조성물 및 방법
JPWO2020219770A5 (https=)
JPWO2021087368A5 (https=)
JPWO2020219775A5 (https=)
JPWO2020219778A5 (https=)

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20220909

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230419

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20231017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231017